Dr Sudarshan Rajagopal

Quick facts

Phase 3 pipeline

• Macitentan Tablets · Cardiovascular
  Macitentan is a dual endothelin receptor antagonist that blocks both ETA and ETB receptors to reduce pulmonary vascular resistance and improve exercise capacity in pulmonary arterial hypertension.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Dr Sudarshan Rajagopal portfolio CI brief
• Dr Sudarshan Rajagopal pipeline updates RSS